Compare ResMed Inc. (RMD) vs Vanguard Intermediate Term Corporate Bond ETF (VCIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Intermediate Term Corporate Bond ETF — how do they compare? ResMed Inc. trades at $194.03 (market cap $28.81B), while Vanguard Intermediate Term Corporate Bond ETF trades at $81.54. The key difference: ResMed Inc. pays a 1.21% dividend while Vanguard Intermediate Term Corporate Bond ETF pays none. Which is the better fit depends on your goals.
| RMD | VCIT | |
|---|---|---|
Market Cap | $28.81B | — |
Sector | Health | Fixed Income |
52-Week High | $293.73 | $84.82 |
52-Week Low | $182.82 | $81.45 |
Enterprise Value | $27.99B | — |
Dividend Yield | 1.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
VCIT trades at $81.71, down 0.28% on the day, with a bearish technical signal driven by moving averages. The fund provides exposure to intermediate-term corporate bonds, offering a competitive yield and low expense ratio. Recent news highlights its role in fixed-income portfolios, comparing favorably on cost and income potential against peers like iShares alternatives.
Outlook remains cautious near-term due to technical weakness, but the fund's low-cost structure and steady dividends appeal for income-focused investors. Risks include interest rate sensitivity and corporate credit conditions, requiring monitoring of economic indicators for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →
